Animal studies have shown that T-DXd can slow tumor progression and enhance survival outcomes in both HER-2-positive and HER-2-negative brain metastases (27), We found no statistically significant difference in PFS between patients with and without brain metastases in our cohort. The gene discussed is ERBB2; the disease is neoplasm.